Targeting p300/CBP axis in lethal prostate cancer
Aiming to transform outcomes and quality of life for people with cancer
Inobrodib is a small molecule inhibitor, taken orally as a simple capsule. It inhibits p300 and CBP through binding into the conserved bromodomain of the twin proteins. This impacts the expression of key cancer drivers including MYC, IRF4 and the androgen receptor (AR) and its variants.
investigated over time by the CellCentric team
investigated over time by the CellCentric team
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Inobrodib is a first-in-class clinical inhibitor of p300/CBP and is being applied to treat a number of specific cancer types that are currently under addressed:
Stand first — Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod temp incididunt ut labore et dolore magna aliqua. Odio tempor orci dapibus ultrices in. Morbi leo urna molestie at. Tortor at auctor urna nunc id. Sodales neque sodales ut etiam sit amet nisl purus in. Diam vulputate ut pharetra sit amet aliquam.
Paragraph 1 — Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incidid ut labore et dolore magna aliqua. Odio tempor orci dapibus ultrices in. Morbi leo urna molestie at. Tort at auctor urna nunc id. Sodales neque sodales ut etiam sit amet nisl purus in. Diam vulputate ut pharet sit amet aliquam. Auctor neque vitae tempus quam pellentesque nec nam aliquam sem. Proin nibh nis condimentum id venenatis a condimentum vitae sapien.
Paragraph 2 — Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incidid ut labore et dolore magna aliqua. Odio tempor orci dapibus ultrices in. Morbi leo urna molestie at. Tort at auctor urna nunc id. Sodales neque sodales ut etiam sit amet nisl purus in. Diam vulputate ut pharet sit amet aliquam.
Paragraph 3 — Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incidid ut labore et dolore magna aliqua. Odio tempor orci dapibus ultrices in. Morbi leo urna molestie at. Tort at auctor urna nunc id. Sodales neque sodales ut etiam sit amet nisl purus in.
We are delighted to collaborate with the American Cancer Society CAN, gaining insights on needs and preferences of people with multiple myeloma. @ACSCAN
We’ll be at #ASH24, San Diego, Dec 7-10. Sharing latest Phase II clinical data on our pioneering p300/CBP oral inhibitor drug, inobrodib.
Karen and Debbie are in Rio for #IMS24. Our novel oral drug for R/R multiple myeloma is in Phase II trials. #MMSM #multiplemyeloma
We are delighted to collaborate with the American Cancer Society CAN, gaining insights on needs and preferences of people with multiple myeloma. @ACSCAN
We’ll be at #ASH24, San Diego, Dec 7-10. Sharing latest Phase II clinical data on our pioneering p300/CBP oral inhibitor drug, inobrodib.
Karen and Debbie are in Rio for #IMS24. Our novel oral drug for R/R multiple myeloma is in Phase II trials. #MMSM #multiplemyeloma
We are delighted to collaborate with the American Cancer Society CAN, gaining insights on needs and preferences of people with multiple myeloma. @ACSCAN
We’ll be at #ASH24, San Diego, Dec 7-10. Sharing latest Phase II clinical data on our pioneering p300/CBP oral inhibitor drug, inobrodib.
Karen and Debbie are in Rio for #IMS24. Our novel oral drug for R/R multiple myeloma is in Phase II trials. #MMSM #multiplemyeloma
Latest press releases
Haematological cancers
Relapsed/refractory haematological cancers including Acute Myeloid Leukemia (AML), Multiple Myeloma (MM), Non-Hodgkin’s Lymphoma(NHL) and Myelodysplastic Syndromes (MDS)
Prostate
Cancer
Metastatic Castration Resistant Prostate Cancer (mCRPC). Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt
Targeted Tumours
inobrodib can potentially target tumours with amplified expression of certain tumour driving proteins that are regulated by p300/CBP.
Inobrodib was developed by CellCentric from initial hits through to an optimised compound and onto a clinical candidate. The compound has been evaluated extensively non-clinically, demonstrating its impact on p300/CBP inhibition in vivo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ac tortor vitae purus faucibus ornare. Viverra justo nec ultrices dui sapien eget. Metus aliquam eleifend mi in nulla posuere sollicitudin aliquam. Nisi est sit amet facilisis magna etiam tempor.
Mi ipsum faucibus vitae aliquet nec ullamcorper. Turpis egestas sed tempus urna et pharetra pharetra massa. Metus dictum at tempor commodo. Porttitor leo a diam sollicitudin tempor id eu nisl. Habitant morbi tristique senectus et netus et malesuada fames. Ullamcorper a lacus vestibulum sed arcu.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ac tortor vitae purus faucibus ornare. Viverra justo nec ultrices dui sapien eget. Metus aliquam eleifend mi in nulla posuere sollicitudin aliquam. Nisi est sit amet facilisis magna etiam tempor.
Inobrodib was developed by CellCentric from initial hits through to an optimised compound and onto a clinical candidate.
The compound has been evaluated extensively non-clinically, demonstrating its impact on p300/CBP inhibition in vivo.
View and download posters from recent key conferences
Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma
Inobrodib: A novel small molecule inhibitor of p300/CBP for the treatment of acute myeloid leukaemia and multiple myeloma
An open-label Phase I/IIa study to evaluate the safety and efficacy of Inobrodib, a first in clinic inhibitor of the p300/CBP bromodomains, as monotherapy in patients with advanced haematological malignancies
An open-label Phase I/IIa study to evaluate the safety and efficacy of Inobrodib as monotherapy and in combination in patients with advanced solid/metastatic tumours.
Inobrodib, a potent and selective p300/CBP bromodomain inhibitor, is targeted and differentiated from BET inhibitors in prostate cancer cell lines in vitro.
p300/CBP inhibitor CCS1477 targets 22Rv1 prostate tumour AR and c-Myc gene expression in vivo.
A first-in-class p300/CBP bromodomain inhibitor for the treatment of prostate cancer and hematologic malignancies.
Novel small molecule inhibitor of p300/CBP down-regulates androgen receptor (AR) and c-Myc for the treatment of prostate cancer and beyond
Therapeutic targeting of the p300/CBP bromodomain for the treatment of castration resistant prostate cancer (CRPC)
Targeting the bromodomain of p300/CBP for the treatment of castrate resistant prostate cancer
Characterisation of CCS1477: A novel small molecule inhibitor of p300/CBP for the treatment of CRPC